Notice: This company has been marked as potentially delisted and may not be actively trading. Deciphera Pharmaceuticals (DCPH) Insider Trading & Ownership Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipSustainabilityTrends Deciphera Pharmaceuticals (NASDAQ:DCPH) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.67%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)2Amount OfInsider Selling(Last 12 Months)$58,733.73 Get DCPH Insider Trade Alerts Want to know when executives and insiders are buying or selling Deciphera Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address DCPH Insider Buying and Selling by Quarter Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Deciphera Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails1/16/2024Jama PitmanSVPSell1,624$14.47$23,499.28 1/16/2024Matthew L ShermanEVPSell2,435$14.47$35,234.45 (Data available from 1/1/2013 forward) DCPH Insider Trading Activity - Frequently Asked Questions Who is on Deciphera Pharmaceuticals's Insider Roster? The list of insiders at Deciphera Pharmaceuticals includes Brightstar Associates Llc, Daniel C Martin, Daniel Lee Flynn, Dennis Leo Walsh, Franklin Stuart Friedman, Jama Pitman, Matthew L Sherman, Steven L Hoerter, and Thomas Patrick Kelly. Learn more on insiders at DCPH. What percentage of Deciphera Pharmaceuticals stock is owned by insiders? 4.67% of Deciphera Pharmaceuticals stock is owned by insiders. Learn more on DCPH's insider holdings. Which Deciphera Pharmaceuticals insiders have been buying company stock? The following insiders have purchased DCPH shares in the last 24 months: Brightstar Associates Llc ($29,999,988.00), Dennis Leo Walsh ($152,460.00), and Franklin Stuart Friedman ($138,800.00). How much insider buying is happening at Deciphera Pharmaceuticals? Insiders have purchased a total of 1,687,666 DCPH shares in the last 24 months for a total of $30,291,248.00 bought. Which Deciphera Pharmaceuticals insiders have been selling company stock? The following insiders have sold DCPH shares in the last 24 months: Daniel C Martin ($17,500.90), Daniel Lee Flynn ($51,039.72), Jama Pitman ($58,238.62), Matthew L Sherman ($139,400.31), Steven L Hoerter ($259,307.46), and Thomas Patrick Kelly ($48,525.32). How much insider selling is happening at Deciphera Pharmaceuticals? Insiders have sold a total of 50,953 Deciphera Pharmaceuticals shares in the last 24 months for a total of $690,787.33 sold. More Insider Trading Tools from MarketBeat Related Companies RVMD Insider Trading NUVL Insider Trading LNTH Insider Trading ELAN Insider Trading BPMC Insider Trading CYTK Insider Trading VKTX Insider Trading BBIO Insider Trading CRNX Insider Trading TGTX Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-ReportServiceNow: Will the High-Flyer Finally Split in 2024? This page (NASDAQ:DCPH) was last updated on 12/16/2024 by MarketBeat.com Staff From Our PartnersMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored"This looks and feels like 2000," says investing legendOur senior analyst Dan Ferris says a new surprise crisis could begin at any moment... and this time, he says i...Stansberry Research | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredFirst JFK… next Elon?Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | SponsoredWall Street Icon: “If you wait on this, it will already be too late”...Investing legend Louis Navellier warned us about the stock market crash of 1987... the 2000 dot-com crash… Enr...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Deciphera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Deciphera Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
